Adam Schwartz
Optometrist · Las Vegas, NVNPI 1548359920
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 77.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $10,000 and has fallen 82.3% since, to $1,774 in 2025. Among optometrist clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $93.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- Glaukos Corporation$1K
- Alcon$935
- Bausch & Lomb, A Division Of Bausch Health US, LLC$428
- Tarsus Pharmaceuticals, Inc.$418
- Rxsight Inc$397
- plus $2K from 16 others
Across 56 payments — averaging $5582.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$313K
What the payments were for
- Consulting fees$8003%
- Speaking & faculty fees$15,57559%
- Travel & lodging$1,7647%
- Food & beverage$8,07431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 108 | $20,340 |
| Glaukos Corporation | 30 | $1,326 |
| Alcon | 17 | $935 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $428 |
| Tarsus Pharmaceuticals, Inc. | 17 | $418 |
| Rxsight Inc | 3 | $397 |
| Sun Pharmaceutical Industries Inc. | 12 | $369 |
| Oyster Point Pharma, Inc. | 17 | $348 |
| Amgen(2 entities) | 11 | $302 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $282 |
| Coopervision Inc. | 5 | $240 |
| Novartis | 6 | $203 |
| Bausch & Lomb Americas Inc. | 7 | $157 |
| Synergeyes, Inc. | 5 | $146 |
| Mallinckrodt Hospital Products Inc. | 5 | $111 |
| Harrow Eye, LLC | 3 | $84 |
| Aerie Pharmaceuticals, Inc. | 2 | $31 |
| Dompe US, Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$17,448
- COMBIGAN$6,182
- ALPHAGAN P$1,743
- DURYSTA$925
- RXSIGHT CONTACT LENS$397
- RXSIGHT INJECTOR CARTRIDGE$397
- RXSIGHT INJECTOR HANDPIECE$397
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$397
- iStent$276
- LIGHT ADJUSTABLE LENS (LAL)$266
- Hydrus Microstent$261
- iDose$155
- AcrySof IQ VIVITY IOL$147
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$130
- VUITY$127
- CEQUA$125
- TEPEZZA$125
- IACCESS$123
- ENVISTA$121
- XDEMVY$117
How this compares
$26,212 in reported general payments places this provider in the 95th percentile of 494 optometrist providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 199 | $237,095 |
| LumiganBimatoprost | 313 | $137,660 |
| XiidraLifitegrast | 42 | $45,246 |
| CombiganBrimonidine Tartrate/Timolol | 52 | $22,953 |
| VyzultaLatanoprostene Bunod | 51 | $20,419 |
| Alphagan PBrimonidine Tartrate | 30 | $10,635 |
| TyrvayaVarenicline Tartrate | 11 | $9,597 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $5,270 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $5,111 |
| Latanoprost | 581 | $5,016 |
| Prednisolone Acetate | 79 | $3,759 |
| Travoprost | 31 | $2,719 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $2,349 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 198 | $1,545 |
| Timolol Maleate | 121 | $1,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $20,340 | $408,343594 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $157 | $65,66593 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $348 | $9,59711 claims |
| AlconSimbrinza | $935 | $5,27014 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $31 | $5,11111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 optometrist providers in Nevada.
Other optometrist in Las Vegas
- Eric BrookerLas Vegas$53K
- My VuongLas Vegas$47K
- Chen YoungLas Vegas$46K
- Harlan KopolowLas Vegas$36K
- Jenny WongLas Vegas$34K
- Lawrence WangLas Vegas$12K
- Brian MillerLas Vegas$11K
- Mark MillerLas Vegas$8K
- Victoria MarLas Vegas$8K
- Matthew ChiapaLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.